menu016.png

New epigenetic drug against Mantle Cell Lymphoma

Jun 13, 2018, Drug Target Review (UK)
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL)…

https://www.drugtargetreview.com/news/32438/epigenetic-drug-mantle-cell-lymphoma/

2018 06 13 DrugTargetReview

QUIMATRYX DEVELOPS AN EFFECTIVE EPIGENETIC DRUG AGAINST MANTLE CELL LYMPHOMA

QUIMATRYX has developed an epigenetic drug that has shown great efficacy in animal models against Mantle Cell Lymphoma.

https://lymphomanewstoday.com/2018/06/21/qtx125-slows-mantle-cell-lymphoma-progression-mouse-study/

Investor search in Quimatryx

Quimatryx has hired NORGESTION to search for one or more partners to rise €3 Million in two planned financial rounds between 2018 and 2019. This amount will be used to develop Quimatryx compound QTX125 (selective inhibitor against HDAC6) to clinical phase I for mantle cell lymphoma.

 

   QUIMATRYX

   Paseo Mikeletegi 69, 3┬¬ planta

   20009 San Sebasti├ín

   Tel: 946 08 70 37

   www.quimatryx.com